Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads
-
最新报道：Propanc Biopharma (NASDAQ: PPCB) has strengthened its intellectual property portfolio with a new US patent covering the clinical dose of its lead cancer therapy PRP, bringing its total to 90 patents globally. Concurrently, the biotech firm announced plans to acquire $100 million worth of Ethereum over the next 12 months as part of a digital asset diversification strategy to support clinical development without excessive equity dilution. This dual approach mirrors treasury strategies adopted by companies like MicroStrategy and BitMine, combining patent protection with crypto assets to finance drug development. Propanc aims to begin Phase 1B trials for its proenzyme-based cancer treatment targeting solid tumors next year.
下一篇
MNT discount purchases are now available, helping investors seize market opportunities with Bybit's advanced financial managemen
- On September 22nd, Bijie.com announced that the MNT discount purchase product has been off...
24小时热点
热点专题
407297